الفهرس 
Hepatic virusesOnly 14 pages are availabe for public view
 |  | from | 186 |  |  |
| | | from | 186 | | |
Abstract
Hepatitis C virus (HCV) is a leading cause for chronic liver diseases and
it was already recorded that at least 170 million people worldwide are HCV
infected. It accounts for 20 to 30% of cases of acute hepatitis. To date at least six
major genotypes are recognized, each having multiple subtypes, have been
identified worldwide. The different genotypes are relevant to epidemiology,
vaccine development, and clinical management of chronic HCV infection. HCV
genotype 4 is mostly predominant in Egypt. At the moment the only accepted
antiviral therapy with proven effectiveness is a combination of PEG-ylated
Interferon α and Ribavirin
The present work was aiming to evaluate the efficency of 3 current
available antiviral drugs either they derived biotechnology (IFN) or synthetically
(Ribavirin and DDB). The present work also gave a highlight on the maximum
bioavilability of such drugs when they applied singly or mixed togather for
synergetic promotion activity. Since the mode of action of antiviral drugs was
vary among them. It was well establised that the mechanism of action of IFN act
on the synthesis of MX protein production developed post expression of MX
gene as a biomarker that initiates MX protein production. This protein interferes
(inhibit) the replication cycle of viruses. MX gene was detected in the human
and animal tissues as Mxa and MXb.
In this study, two cell lines namely African green monkey cells (Vero)
and Human hepatoma cells (HepG2 cells) were maintained , splitted and
preserved in cell bank of target cell lines according to established protocols.
Seed stock of Vesicular Stomatitis virus (model virus was used instead of HCV) seed stock was prepared in Vero cells then virus infectivity titer end point was
determined 107.68 TCCD50.
The results of this study can be summarized in the following:
1- Cytotoxicity of Interferon alpha-2a, Ribavirin and DDB was carried
out on Vero and HepG2 cell lines. Evaluation of residual living cells was
arranged using MTT assay. The results revealed that Interferon was completely
safe to both cell lines at any appplied concentration where no toxicity was
detected. While toxicity of Ribavirin to Vero and HepG2 cell lines showed a
residual viability in the order of 60% and 58% when used at 1200 μg/ml. While,
the concentration of 300μg/ml showed 100 % safety for both cell lines either
treated with Ribavirin or DDB.
2- Evaluation of antiviral activity under the effect of antiviral drugs on
both cell lines revealed that the reactivity of Vero cells to antiviral drugs was
somewhat better than that of HepG2 cells. A better pattern to antiviral activity
for both Interferon and Ribavirin while a less effective role to DDB as antiviral
was detected in Vero cell line. The least effect on viral infectivity titer was
detected on HepG2 cell lines by using DDB.